Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae, including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). - skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). - urinary tract infections, both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter spp.; proteus spp., including proteus mirabilis and indole-positive proteus; klebsiella spp.; and escherichia coli. - bacterial septicemia caused by pseudomonas aeruginosa, klebsiella spp., haemophilus influenzae , escherichia coli , serratia spp., streptococcus pneumoniae , and staphylococcus aureus (methicillin-susceptible strains). - bone and joint infections caused by pseudomonas aeruginosa, klebsiella spp., enterobacter spp., and staphylococcus aureus (methicillin-susceptible strains). - gynecologic infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by escherichia coli. - intra-abdominal infections, including peritonitis caused by escherichia coli, klebsiella spp., and staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and bacteroides spp. (many strains of bacteroides fragilis are resistant). - central nervous system infections, including meningitis, caused by haemophilus influenzae and neisseria meningitidis. ceftazidime has also been used successfully in a limited number of cases of meningitis due to pseudomonas aeruginosa and streptococcus pneumoniae . ceftazidime for injection, usp may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. ceftazidime for injection, usp may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, usp and other antibacterial drugs, ceftazidime for injection, usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftazidime for injection is contraindicated in patients who have shown hypersensitivity to ceftazidime or the cephalosporin group of antibacterial drugs. ceftazidime for injection, usp instructions for constitution pharmacy bulk package: 6 g - insert the syringe needle through the vial closure and inject 26 ml of diluent. the vacuum may assist entry of the diluent. remove the syringe needle. - shake to dissolve; a clear solution containing approximately 1 g of ceftazidime activity per 5 ml will be obtained in 1 to 2 minutes. - insert a gas-relief needle through the vial closure to relieve the internal pressure. remove the gas-relief needle before extracting any solution. note: to preserve product sterility, it is important that a gas-relief needle is not inserted through the vial closure before the product has dissolved. sagent® mfd. for sagent pharmaceuticals schaumburg, il 60195 (usa) made in brazil ©2020 sagent pharmaceuticals, inc. revised: june 2020 sagent pharmaceuticals®

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - ceftazidime - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; ceftazidime

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - ceftazidime - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; ceftazidime

Israel - engleză - Ministry of Health

vitamed pharmaceutical industries ltd - ceftazidime as pentahydrate - powder for solution for inj/inf - ceftazidime as pentahydrate 2 g/vial - ceftazidime - ceftazidime-vit 2 g is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).•nosocomial pneumonia•broncho-pulmonary infections in cystic fibrosis•bacterial meningitis•chronic suppurative otitis media•malignant otitis externa•complicated urinary tract infections•complicated skin and soft tissue infections•complicated intra-abdominal infections•bone and joint infections•peritonitis associated with dialysis in patient on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. ceftazidime vit 2 g may be used in the management of neutropenic patients with fever that is suspected to be due to abacterial infection. ceftazidime vit 2 g may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp). the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria. ceftazidime vit 2 g should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity. consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Canada - engleză - Health Canada

fresenius kabi canada ltd - ceftazidime - powder for solution - 1g - ceftazidime 1g - third generation cephalosporins

Canada - engleză - Health Canada

fresenius kabi canada ltd - ceftazidime - powder for solution - 6g - ceftazidime 6g - third generation cephalosporins

Canada - engleză - Health Canada

fresenius kabi canada ltd - ceftazidime - powder for solution - 2g - ceftazidime 2g - third generation cephalosporins

Canada - engleză - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 1g - ceftazidime (ceftazidime pentahydrate) 1g - third generation cephalosporins

Canada - engleză - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 2g - ceftazidime (ceftazidime pentahydrate) 2g - third generation cephalosporins

Canada - engleză - Health Canada

sterimax inc - ceftazidime (ceftazidime pentahydrate) - powder for solution - 6g - ceftazidime (ceftazidime pentahydrate) 6g - third generation cephalosporins